IN8bio, Inc. (NASDAQ:INAB) Expected to Earn Q1 2024 Earnings of ($0.15) Per Share

IN8bio, Inc. (NASDAQ:INAB) – Stock analysts at Zacks Small Cap issued their Q1 2024 earnings per share (EPS) estimates for IN8bio in a report issued on Monday, April 22nd. Zacks Small Cap analyst J. Vandermosten expects that the company will earn ($0.15) per share for the quarter. The consensus estimate for IN8bio’s current full-year earnings is ($0.64) per share. Zacks Small Cap also issued estimates for IN8bio’s Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.58) EPS, FY2025 earnings at ($0.59) EPS and FY2026 earnings at ($0.60) EPS.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of IN8bio in a research note on Wednesday, April 10th. Laidlaw assumed coverage on IN8bio in a research note on Monday, March 18th. They issued a “buy” rating and a $7.50 price target on the stock.

IN8bio Trading Down 1.9 %

NASDAQ:INAB opened at $1.04 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.57 and a current ratio of 4.57. IN8bio has a one year low of $0.65 and a one year high of $3.48. The business’s 50-day simple moving average is $1.13 and its 200 day simple moving average is $1.15. The stock has a market cap of $33.27 million, a price-to-earnings ratio of -1.03 and a beta of -0.01.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, March 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.05).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Voss Capital LLC raised its stake in IN8bio by 11.7% during the third quarter. Voss Capital LLC now owns 511,584 shares of the company’s stock valued at $532,000 after buying an additional 53,708 shares in the last quarter. Rock Creek Group LP raised its stake in IN8bio by 98.3% during the third quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock valued at $157,000 after buying an additional 75,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc raised its stake in IN8bio by 85.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock valued at $109,000 after buying an additional 36,179 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in IN8bio during the fourth quarter valued at approximately $5,216,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.